|
1
|
Okamoto W, Okamoto I, Yoshida T, Okamoto
K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara
K, et al: Identification of c-Src as a potential therapeutic target
for gastric cancer and of MET activation as a cause of resistance
to c-Src inhibition. Mol Cancer Ther. 9:1188–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society: Cancer Facts and
Figures 2016. ACS; Atlanta, GA: 2016, http://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html.
Accessed date January 24, 2017.
|
|
3
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yasui W, Hata J, Yokozaki H, Nakatani H,
Ochiai A, Ito H and Tahara E: Interaction between epidermal growth
factor and its receptor in progression of human gastric carcinoma.
Int J Cancer. 41:211–217. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mi L, Ji X and Ji J: Prognostic biomarker
in advanced gastric cancer. Transl Gastrointest Cancer. 5:16–29.
2016.
|
|
6
|
Aydin K, Okutur SK, Bozkurt M, Turkmen I,
Namal E, Pilanci K, Ozturk A, Akcali Z, Dogusoy G and Demir OG:
Effect of epidermal growth factor receptor status on the outcomes
of patients with metastatic gastric cancer: A pilot study. Oncol
Lett. 7:255–259. 2014.
|
|
7
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moser C, Lang SA and Stoeltzing O:
Heat-shock protein 90 (Hsp90) as a molecular target for therapy of
gastrointestinal cancer. Anticancer Res. 29:2031–2042.
2009.PubMed/NCBI
|
|
9
|
Wang Y, Trepel JB, Neckers LM and Giaccone
G: STA-9090, a small-molecule Hsp90 inhibitor for the potential
treatment of cancer. Curr Opin Investig Drugs. 11:1466–1476.
2010.PubMed/NCBI
|
|
10
|
Jhaveri K and Modi S: Ganetespib: Research
and clinical development. Onco Targets Ther. 8:1849–1858.
2015.PubMed/NCBI
|
|
11
|
Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan
L, Lian C, Shi H, Chen K and Tu Z: Targeting heat-shock protein 90
with ganetespib for molecularly targeted therapy of gastric cancer.
Cell Death Dis. 6:e15952015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mahata S, Maru S, Shukla S, Pandey A,
Mugesh G, Das BC and Bharti AC: Anticancer property of Bryophyllum
pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC
Complement Altern Med. 12:152012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takayama S, Reed JC and Homma S:
Heat-shock proteins as regulators of apoptosis. Oncogene.
22:9041–9047. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jhaveri K, Ochiana SO, Dunphy MP,
Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM,
Koren J III, Modi S, et al: Heat shock protein 90 inhibitors in the
treatment of cancer: Current status and future directions. Expert
Opin Investig Drugs. 23:611–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Den RB and Lu B: Heat shock protein 90
inhibition: Rationale and clinical potential. Ther Adv Med Oncol.
4:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lai CH, Park KS, Lee DH, Alberobello AT,
Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y and Giaccone
G: HSP-90 inhibitor ganetespib is synergistic with doxorubicin in
small cell lung cancer. Oncogene. 33:4867–4876. 2014. View Article : Google Scholar :
|
|
17
|
Smith DL, Acquaviva J, Sequeira M, Jimenez
JP, Zhang C, Sang J, Bates RC and Proia DA: The HSP90 inhibitor
ganetespib potentiates the antitumor activity of EGFR tyrosine
kinase inhibition in mutant and wild-type non-small cell lung
cancer. Target Oncol. 10:235–245. 2015. View Article : Google Scholar :
|
|
18
|
Acquaviva J, Smith DL, Jimenez JP, Zhang
C, Sequeira M, He S, Sang J, Bates RC and Proia DA: Overcoming
acquired BRAF inhibitor resistance in melanoma via targeted
inhibition of Hsp90 with ganetespib. Mol Cancer Ther. 13:353–363.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wainberg ZA, Anghel A, Rogers AM, Desai
AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, et
al: Inhibition of HSP90 with AUY922 induces synergy in
HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol
Cancer Ther. 12:509–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Burrows F, Zhang H and Kamal A: Hsp90
activation and cell cycle regulation. Cell Cycle. 3:1530–1536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Srethapakdi M, Liu F, Tavorath R and Rosen
N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma
gene product-dependent G1 arrest. Cancer Res. 60:3940–3946.
2000.PubMed/NCBI
|
|
22
|
Foijer F and te Riele H: Check, double
check: The G2 barrier to cancer. Cell Cycle. 5:831–836. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
DiPaola RS: To arrest or not to G(2)-M
Cell-cycle arrest: commentary re: A.K. Tyagi et al., Silibinin
strongly synergizes human prostate carcinoma DU145 cells to
doxorubicin-induced growth inhibition, G(2)-M arrest, and
apoptosis. Clin Cancer Res. 8:3512–3519. 2002.
Clin Cancer Res. 8:3311–3314. 2002.
|
|
24
|
Toyoshima H and Hunter T: p27 a novel
inhibitor of G1 cyclin-Cdk protein kinase activity, is related to
p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foijer F, Delzenne-Goette E, Dekker M and
Te Riele H: In vivo significance of the G2 restriction point.
Cancer Res. 67:9244–9247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sawai H and Domae N: Discrimination
between primary necrosis and apoptosis by necrostatin-1 in Annexin
V-positive/propidium iodide-negative cells. Biochem Biophys Res
Commun. 411:569–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lang SA, Klein D, Moser C, Gaumann A,
Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler
EK, et al: Inhibition of heat shock protein 90 impairs epidermal
growth factor-mediated signaling in gastric cancer cells and
reduces tumor growth and vascularization in vivo. Mol Cancer Ther.
6:1123–1132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu C, Liu D, Jin J, Deokar H, Zhang Y,
Buolamwini JK, Yu X, Yan C and Chen X: Inhibition of gastric tumor
growth by a novel Hsp90 inhibitor. Biochem Pharmacol. 85:1246–1256.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh
DY and Bang YJ: Antitumor activity of NVP-AUY922, a novel heat
shock protein 90 inhibitor, in human gastric cancer cells is
mediated through proteasomal degradation of client proteins. Cancer
Sci. 102:1388–1395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimamura T, Perera SA, Foley KP, Sang J,
Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, et al:
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has
potent antitumor activity in in vitro and in vivo models of
non-small cell lung cancer. Clin Cancer Res. 18:4973–4985. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Socinski MA, Goldman J, El-Hariry I,
Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H,
Sequist LV, et al: A multi-center phase II study of ganetespib
monotherapy in patients with genotypically defined advanced
non-small cell lung cancer. Clin Cancer Res. 19:3068–3077. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramalingam S, Goss G, Rosell R,
Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric
T, Khuri F, et al: A randomized phase II study of ganetespib, a
heat shock protein 90 inhibitor, in combination with docetaxel in
second-line therapy of advanced non-small cell lung cancer
(GALAXY-1). Ann Oncol. 26:1741–1748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jhaveri K, Chandarlapaty S, Lake D,
Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S,
Wasserheit-Leiblich C, Fasano J, et al: A phase II open-label study
of ganetespib, a novel heat shock protein 90 inhibitor for patients
with metastatic breast cancer. Clin Breast Cancer. 14:154–160.
2014. View Article : Google Scholar : PubMed/NCBI
|
